PULM - Pulmatrix, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.9090
-0.0085 (-0.93%)
At close: 3:32PM EDT

0.9200 +0.01 (1.21%)
After hours: 4:16PM EDT

Stock chart is not supported by your current browser
Previous Close0.9175
Open0.9144
Bid0.1000 x 2900
Ask1.0000 x 1200
Day's Range0.8810 - 0.9300
52 Week Range0.7200 - 5.2000
Volume97,827
Avg. Volume482,614
Market Cap16.625M
Beta (3Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-3.8560
Earnings DateMay 3, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Trade prices are not sourced from all markets
  • Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix
    Zackslast month

    Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

    Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

  • Bet on 5 Top Stocks With Rising P/E
    Zackslast month

    Bet on 5 Top Stocks With Rising P/E

    Bet on these top-ranked stocks with rising P/E to realize outsized gains.

  • Pulmatrix Announces Leadership Change
    PR Newswire2 months ago

    Pulmatrix Announces Leadership Change

    LEXINGTON, Mass., May 16, 2019 /PRNewswire/ -- Pulmatrix, Inc. (PULM) announces today that Dr. Robert Clarke has stepped down as Chief Executive Officer.  Ted Raad will immediately transition from his current role as Chief Business Officer to that of Chief Executive Officer and member of the Pulmatrix Board of Directors. In order to ensure a smooth transition, Dr. Clarke will continue as an advisor to the Board of Directors and Company Management through August 14, 2019.

  • Pulmatrix Reports Q1 2019 Results
    PR Newswire2 months ago

    Pulmatrix Reports Q1 2019 Results

    LEXINGTON, Mass. , May 15, 2019 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone in the first quarter with the FDA providing approval ...

  • Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole™
    PR Newswire3 months ago

    Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole™

    - Transaction marks Cipla's entry into specialty respiratory segment, building on inroads made into the specialty business in the recent past - iSPERSE™ formulation of the anti-fungal drug itraconazole ...

  • Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering
    PR Newswire3 months ago

    Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering

    LEXINGTON, Mass., April 8, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the closing of its previously announced underwritten public offering of an aggregate of 1,719,554 common units and 8,947,112 pre-funded units at a price to the public of $1.35 per common unit and $1.34 per pre-funded unit, as well as the purchase of an additional 1,599,999 shares of common stock and common warrants to purchase an additional 1,599,999 shares of common stock purchased pursuant to the exercise in full of the underwriter's option to purchase additional securities. Each common unit contains one share of common stock (or, in the case of the pre-funded units, one pre-funded warrant) and one common warrant to purchase a share of common stock.

  • Pulmatrix, Inc. Announces Pricing of $14.4 Million Upsized Public Offering
    PR Newswire3 months ago

    Pulmatrix, Inc. Announces Pricing of $14.4 Million Upsized Public Offering

    LEXINGTON, Mass., April 3, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the pricing of its previously announced underwritten public offering of an aggregate of 10,666,666 units at a price to the public of $1.35 per unit. Each unit is comprised of one share of common stock (or common stock equivalent) and one warrant to purchase one share of common stock. In addition, the Company has granted the underwriter a 30-day option to purchase up to 1,599,999 additional shares of common stock and/or warrants to purchase 1,599,999 shares of common stock.

  • Pulmatrix News: PULM Stock Skyrockets on Asthma Drug Deal
    InvestorPlace4 months ago

    Pulmatrix News: PULM Stock Skyrockets on Asthma Drug Deal

    Pulmatrix (NASDAQ:PULM) was the big winner of the biopharmaceutical space on Monday and possibly the rest of the week as the company's stock went through the roof early in the day off the heels of a "binding term sheet" surrounding one of its most asthma treatments.Source: FlickrThe Lexington, Mass.-based drug maker said that it had entered into the aforementioned term sheet with Cipla Ltd, a subsidiary of Cipla Technologies LLC, in regards to the development and commercialization of its asthma treatment Pulmazole.The terms of the deal will require Cipla to make an upfront payment to Pulmatrix of $22 million, giving it access to all rights of Pulmazole. However, the deal also states that Pulmatrix will retain the right to garner 50% of the free cash flow from future sales of the asthma treatment.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe Mass.-based business said that once the deal is done and dusted, the company sees itself in a good position to complete the phase 2 study of Pulmazole, which it plans to make a reality during the second quarter of 2019.PULM stock had a day to remember as the stock went gangbusters, gaining 81.9% by day's end. The deal also led to a massive spike in trading volume for Pulmatrix as 48.2 million shares traded hand, compared to only 834,000 shares as the full-day average before today.Share retraced about 1.7% during after-hours trading. More From InvestorPlace * The Elite 8 Stocks to Buy for Massive Outperformance * 7 Reasons to Buy Housing Stocks in 2019 * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos Compare Brokers The post Pulmatrix News: PULM Stock Skyrockets on Asthma Drug Deal appeared first on InvestorPlace.

  • Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole
    PR Newswire4 months ago

    Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole

    The Binding Term Sheet Executed on April 1, 2019 Lays Groundwork for Entry into a Definitive Agreement During the 2nd Quarter of 2019 LEXINGTON, Mass. , April 1, 2019 /PRNewswire/ -- Pulmatrix, Inc . (NASDAQ: ...

  • Pulmatrix to Participate in Upcoming Investor Conferences
    PR Newswire4 months ago

    Pulmatrix to Participate in Upcoming Investor Conferences

    Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor in development to treat Acute Exacerbations in Chronic Obstructive Pulmonary Disease (AECOPD).

  • Pulmatrix Regains NASDAQ Compliance
    PR Newswire4 months ago

    Pulmatrix Regains NASDAQ Compliance

    The letter received noted that for 10 consecutive business days, from February 26, 2019 to March 11, 2019, the closing bid price of the Company's common stock was $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is closed. Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor in development to treat Acute Exacerbations in Chronic Obstructive Pulmonary Disease (AECOPD).

  • ACCESSWIRE4 months ago

    These Four Tech Stocks Could Set The Pace On Friday

    Over the course of the last few months, we've seen tech companies cause quite a commotion in the market because of their determination to use design-thinking and strategically develop products and ideas for the betterment of consumers. ParcelPal Technology Inc (PTNYF) (PKG), MicroVision Inc (MVIS), Pulmatrix Inc (PULM), and Xunlei Limited (XNET) represent 4 tech stocks on the rise on Friday. ParcelPal Technology Inc (PTNYF) (PKG) is a technology-driven logistics company purposed with connecting consumers to the goods they love.

  • Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline
    PR Newswire5 months ago

    Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline

    LEXINGTON, Mass. , Feb. 19, 2019 /PRNewswire/ --  Pulmatrix, Inc . (NASDAQ: PULM) today announces 2018 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary ...

  • Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs
    PR Newswire5 months ago

    Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs

    LEXINGTON, Mass., Feb. 12, 2019 /PRNewswire/ -- Pulmatrix, Inc. (PULM) has been awarded five new patents that expand the intellectual property protection for Pulmatrix's PUR1800 and PUR5700 programs.  These patents expand the intellectual property protection for Pulmatrix's novel Inhaled Narrow Spectrum Kinase Inhibitors which were in licensed from Janssen in June 2017. The US Patent Office granted US Patent No. 9,993,478 B2, which claims dry powder formulations that contain certain narrow spectrum kinase inhibitors as the active pharmaceutical ingredient and cover dry powder formulations of the in licensed compound RV-1162.  RV-1162 is the active pharmaceutical ingredient in PUR1800.

  • Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market
    PR Newswire5 months ago

    Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market

    LEXINGTON, Mass., Feb. 8, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 1,706,484 shares of common stock at a price of $1.465 per share in a registered direct offering priced at-the-market, resulting in total gross proceeds of approximately $2.5 million. The Company also agreed to issue to the investors unregistered warrants to purchase up to 1,706,484 shares of common stock. The warrants have an exercise price of $1.34 per share of common stock, will be exercisable immediately and will expire five and one-half years following the date of issuance.

  • Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study
    PR Newswire5 months ago

    Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study

    Pulmatrix notified of FDA's authorization to proceed for a Phase 2 study of Pulmazole (inhaled itraconazole) in asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA) LEXINGTON, Mass. , ...

  • ACCESSWIRE5 months ago

    4 Biotech Stocks Making Moves on Wednesday (2/6/19)

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), Pulmatrix Inc (PULM), MacroGenics Inc (MGNX), and Proteostasis Therapeutics Inc (PTI) represent four biotech companies creating nuanced approaches to further the advancement of modern medicine. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments which demonstrate Premier's dedication to the betterment of the biotech industry, and more importantly, to consumers looking to enhance their quality of life. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced at the tail-end of last month that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1
    PR Newswire5 months ago

    Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1

    LEXINGTON, Mass., Feb. 6, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the termination of its previously planned underwritten public offering, with Oppenheimer & Co., Inc. as sole bookrunner, pursuant to a Registration Statement on Form S-1, File No. 333-229092. Pulmatrix filed with the Securities and Exchange Commission (the "SEC") a request to withdraw the Registration Statement, initially filed with the SEC on December 28, 2018. The Company requested to withdraw the Registration Statement due to market conditions and for strategic reasons.

  • Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split
    PR Newswire5 months ago

    Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split

    LEXINGTON, Mass., Feb. 5, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced a 1-for-10 reverse split of its common stock, effective as of 5:00 pm Eastern Time, February 5, 2019. Beginning on February 6, 2019, the Company's common stock will trade on the NASDAQ Capital Market on a split adjusted basis. At the Company's 2018 annual meeting of stockholders on June 5, 2018, the Company's stockholders authorized the Board of Directors, in its discretion but prior to the annual meeting of our stockholders in 2019, to amend the Amended and Restated Certificate of Incorporation of the Company to effect a reverse stock split at a ratio in the range of 1-for-4 to 1-for-10.

  • Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock
    PR Newswire5 months ago

    Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock

    LEXINGTON, Mass., Feb. 5, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the closing and funding of its previously announced underwritten public offering of 5,323,530 shares of its common stock at a price to the public of $0.17 per share. Pulmatrix currently intends to use the net proceeds from the offering for working capital and general corporate purposes. A shelf registration statement on Form S-3 (Registration No. 333-212546) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and was declared effective on August 3, 2016.

  • Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock
    PR Newswire6 months ago

    Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock

    LEXINGTON, Mass., Jan. 30, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the pricing of an underwritten public offering of 5,323,530 shares of its common stock at a price to the public of $0.17 per share. Pulmatrix expects to receive aggregate gross proceeds of approximately $905,000 from the offering. The offering is expected to close on or about February 4, 2019, subject to customary closing conditions.

  • Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock
    PR Newswire6 months ago

    Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock

    LEXINGTON, Mass., Jan. 30, 2019 /PRNewswire/ – Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.